INZY – inozyme pharma, inc. (US:NASDAQ)
Stock Stats
News
Here's Why Inozyme Pharma (INZY) is Poised for a Turnaround After Losing -29.98% in 4 Weeks [Yahoo! Finance]
Inozyme Pharma to Present at Upcoming Investor Conferences
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $23.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Inozyme Pharma, Inc. (NASDAQ: INZY) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, down previously from $15.00.
Form SC 13G/A Inozyme Pharma, Inc. Filed by: EVENTIDE ASSET MANAGEMENT, LLC
Form SC 13G Inozyme Pharma, Inc. Filed by: BlackRock, Inc.
Form 10-Q Inozyme Pharma, Inc. For: Sep 30
Form 8-K Inozyme Pharma, Inc. For: Nov 05
Form 8-K Inozyme Pharma, Inc. For: Oct 24
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.